Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 10
2021 37
2022 27
2023 32
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
Kanegane H, Endo A, Okada S, Ohnishi H, Ishimura M, Nishikomori R, Imai K, Nonoyama S, Muramatsu H, Wada T, Kuga A, Sakamoto K, Russo-Schwarzbaum S, Chu LH, McCoy B, Li Z, Yel L. Kanegane H, et al. Immunother Adv. 2024 Mar 1;4(1):ltae001. doi: 10.1093/immadv/ltae001. eCollection 2024. Immunother Adv. 2024. PMID: 38511087 Free PMC article.
Cancer vaccines: from an immunology perspective.
Makker S, Galley C, Bennett CL. Makker S, et al. Immunother Adv. 2023 Dec 21;4(1):ltad030. doi: 10.1093/immadv/ltad030. eCollection 2024. Immunother Adv. 2023. PMID: 38223410 Free PMC article. Review.
Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function.
Kaneko S, Sakura F, Tanita K, Shimbo A, Nambu R, Yoshida M, Umetsu S, Inui A, Okada C, Tsumura M, Yamada M, Suzuki H, Kosaki K, Ohara O, Shimizu M, Morio T, Okada S, Kanegane H. Kaneko S, et al. Immunother Adv. 2023 Nov 24;3(1):ltad027. doi: 10.1093/immadv/ltad027. eCollection 2023. Immunother Adv. 2023. PMID: 38549698 Free PMC article.
DC-targeting lentivectors for cancer immunotherapy.
Gea-Mallorquí E, Rowland-Jones S. Gea-Mallorquí E, et al. Immunother Adv. 2023 Nov 1;3(1):ltad023. doi: 10.1093/immadv/ltad023. eCollection 2023. Immunother Adv. 2023. PMID: 38020311 Free PMC article. Review.
Correction to: Immunology of allergen immunotherapy.
[No authors listed] [No authors listed] Immunother Adv. 2023 Oct 12;3(1):ltad017. doi: 10.1093/immadv/ltad017. eCollection 2023. Immunother Adv. 2023. PMID: 37841368 Free PMC article.
Prevention vs treatment of rheumatoid arthritis.
Klareskog L, Alfredsson L. Klareskog L, et al. Immunother Adv. 2023 Aug 29;3(1):ltad016. doi: 10.1093/immadv/ltad016. eCollection 2023. Immunother Adv. 2023. PMID: 37662832 Free PMC article. Review.
A historical perspective on HLA.
Bodmer W. Bodmer W. Immunother Adv. 2023 Aug 17;3(1):ltad014. doi: 10.1093/immadv/ltad014. eCollection 2023. Immunother Adv. 2023. PMID: 37636243 Free PMC article. Review.
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial.
Abaasa A, Egesa M, Driciru E, Koopman JPR, Kiyemba R, Sanya RE, Nassuuna J, Ssali A, Kimbugwe G, Wajja A, van Dam GJ, Corstjens PLAM, Cose S, Seeley J, Kamuya D, Webb EL, Yazdanbakhsh M, Kaleebu P, Siddiqui AA, Kabatereine N, Tukahebwa E, Roestenberg M, Elliott AM. Abaasa A, et al. Immunother Adv. 2023 Jul 20;3(1):ltad010. doi: 10.1093/immadv/ltad010. eCollection 2023. Immunother Adv. 2023. PMID: 37538934 Free PMC article.
TIGIT-based immunotherapeutics in lung cancer.
Patel AJ, Middleton GW. Patel AJ, et al. Immunother Adv. 2023 May 26;3(1):ltad009. doi: 10.1093/immadv/ltad009. eCollection 2023. Immunother Adv. 2023. PMID: 37325585 Free PMC article. Review.
Combination CD200R/PD-1 blockade in a humanised mouse model.
Fellermeyer M, Anzilotti C, Paluch C, Cornall RJ, Davis SJ, Gileadi U. Fellermeyer M, et al. Immunother Adv. 2023 Mar 30;3(1):ltad006. doi: 10.1093/immadv/ltad006. eCollection 2023. Immunother Adv. 2023. PMID: 37082107 Free PMC article.
A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate.
Daramola AK, Akinrinmade OA, Fajemisin EA, Naran K, Mthembu N, Hadebe S, Brombacher F, Huysamen AM, Fadeyi OE, Hunter R, Barth S. Daramola AK, et al. Immunother Adv. 2022 Dec 6;3(1):ltac023. doi: 10.1093/immadv/ltac023. eCollection 2023. Immunother Adv. 2022. PMID: 36789295 Free PMC article.
Immunology of allergen immunotherapy.
Rahman RS, Wesemann DR. Rahman RS, et al. Immunother Adv. 2022 Nov 25;2(1):ltac022. doi: 10.1093/immadv/ltac022. eCollection 2022. Immunother Adv. 2022. PMID: 36530352 Free PMC article. Review.
De-risking clinical trial failure through mechanistic simulation.
Brown LV, Wagg J, Darley R, van Hateren A, Elliott T, Gaffney EA, Coles MC. Brown LV, et al. Immunother Adv. 2022 Aug 23;2(1):ltac017. doi: 10.1093/immadv/ltac017. eCollection 2022. Immunother Adv. 2022. PMID: 36176591 Free PMC article.
Correction.
[No authors listed] [No authors listed] Immunother Adv. 2022 Aug 11;2(1):ltac018. doi: 10.1093/immadv/ltac018. eCollection 2022. Immunother Adv. 2022. PMID: 35967910 Free PMC article.
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, Baker L, Velez J, Ramesh R, Wavreille AS, Verneret M, Fan H, Hu T, Xu F, Taraszka J, Pelletier M, Miyashiro J, Rinne M, Dranoff G, Sabatos-Peyton C, Cremasco V. Schwartz S, et al. Immunother Adv. 2022 Aug 10;2(1):ltac019. doi: 10.1093/immadv/ltac019. eCollection 2022. Immunother Adv. 2022. PMID: 36196369 Free PMC article.
Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy.
Schmidt D, Ebrahimabadi S, Gomes KRS, de Moura Aguiar G, Cariati Tirapelle M, Nacasaki Silvestre R, de Azevedo JTC, Tadeu Covas D, Picanço-Castro V. Schmidt D, et al. Immunother Adv. 2022 Feb 3;2(1):ltac003. doi: 10.1093/immadv/ltac003. eCollection 2022. Immunother Adv. 2022. PMID: 35919494 Free PMC article. Review.
Peanut oral immunotherapy: current trends in clinical trials.
Reinwald S, Rolland JM, O'Hehir RE, van Zelm MC. Reinwald S, et al. Immunother Adv. 2022 Jan 31;2(1):ltac004. doi: 10.1093/immadv/ltac004. eCollection 2022. Immunother Adv. 2022. PMID: 35919493 Free PMC article. Review.
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes.
Tatovic D, McAteer MA, Barry J, Barrientos A, Rodríguez Terradillos K, Perera I, Kochba E, Levin Y, Dul M, Coulman SA, Birchall JC, von Ruhland C, Howell A, Stenson R, Alhadj Ali M, Luzio SD, Dunseath G, Cheung WY, Holland G, May K, Ingram JR, Chowdhury MMU, Wong FS, Casas R, Dayan C, Ludvigsson J. Tatovic D, et al. Immunother Adv. 2022 Jan 27;2(1):ltac002. doi: 10.1093/immadv/ltac002. eCollection 2022. Immunother Adv. 2022. PMID: 35919496 Free PMC article.
Immunotherapy advances: One year on.
Elliott T. Elliott T. Immunother Adv. 2022 Jan 11;2(1):ltac001. doi: 10.1093/immadv/ltac001. eCollection 2022. Immunother Adv. 2022. PMID: 35919492 Free PMC article. No abstract available.
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.
Marwaha AK, Chow S, Pesenacker AM, Cook L, Sun A, Long SA, Yang JHM, Ward-Hartstonge KA, Williams E, Domingo-Vila C, Halani K, Harris KM, Tree TIM, Levings MK, Elliott T, Tan R, Dutz JP. Marwaha AK, et al. Immunother Adv. 2021 Nov 13;2(1):ltab022. doi: 10.1093/immadv/ltab022. eCollection 2022. Immunother Adv. 2021. PMID: 35072168 Free PMC article.
Potential human immunotherapeutics for plague.
Andrianaivoarimanana V, Randriantseheno LN, Moore KM, Walker NJ, Lonsdale SG, Kempster S, Almond NA, Rajerison M, Williamson ED. Andrianaivoarimanana V, et al. Immunother Adv. 2021 Oct 5;1(1):ltab020. doi: 10.1093/immadv/ltab020. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919741 Free PMC article. Review.
Oral tolerance as antigen-specific immunotherapy.
Pinheiro-Rosa N, Torres L, Oliveira MA, Andrade-Oliveira MF, Guimarães MAF, Coelho MM, Alves JL, Maioli TU, Faria AMC. Pinheiro-Rosa N, et al. Immunother Adv. 2021 Aug 25;1(1):ltab017. doi: 10.1093/immadv/ltab017. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919733 Free PMC article. Review.
A summary of current NKG2D-based CAR clinical trials.
Curio S, Jonsson G, Marinović S. Curio S, et al. Immunother Adv. 2021 Aug 13;1(1):ltab018. doi: 10.1093/immadv/ltab018. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 34604863 Free PMC article. Review.
Adaptive immunity and vaccination - iron in the spotlight.
Preston AE, Drakesmith H, Frost JN. Preston AE, et al. Immunother Adv. 2021 Jun 17;1(1):ltab007. doi: 10.1093/immadv/ltab007. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919735 Free PMC article. Review.
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors.
Drobni ZD, Murphy SP, Alvi RM, Lee C, Gong J, Mosarla RC, Rambarat PK, Hartmann SB, Gilman HK, Zubiri L, Raghu VK, Sullivan RJ, Zafar A, Zlotoff DA, Sise ME, Guidon AC, Reynolds KL, Dougan M, Neilan TG. Drobni ZD, et al. Immunother Adv. 2021 Jun 16;1(1):ltab014. doi: 10.1093/immadv/ltab014. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 34541581 Free PMC article.
α2-3 Sialic acid binding and uptake by human monocyte-derived dendritic cells alters metabolism and cytokine release and initiates tolerizing T cell programming.
Lübbers J, Eveline Li RJ, Gorki FS, Bruijns SCM, Gallagher A, Kalay H, Ambrosini M, Molenaar D, Van den Bossche J, van Vliet SJ, van Kooyk Y. Lübbers J, et al. Immunother Adv. 2021 Jun 9;1(1):ltab012. doi: 10.1093/immadv/ltab012. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919745 Free PMC article.
Targeting immunometabolism to treat COVID-19.
O'Carroll SM, O'Neill LAJ. O'Carroll SM, et al. Immunother Adv. 2021 Jun 2;1(1):ltab013. doi: 10.1093/immadv/ltab013. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 34240083 Free PMC article. Review.
MicroRNAs: immune modulators in cancer immunotherapy.
Xing Y, Wang Z, Lu Z, Xia J, Xie Z, Jiao M, Liu R, Chu Y. Xing Y, et al. Immunother Adv. 2021 May 13;1(1):ltab006. doi: 10.1093/immadv/ltab006. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919742 Free PMC article. Review.
Integrin-directed antibody-based immunotherapy: focus on VLA-4.
Savino W, Chaves B, Bonomo AC, Cotta-de-Almeida V. Savino W, et al. Immunother Adv. 2021 Feb 9;1(1):ltab002. doi: 10.1093/immadv/ltab002. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919739 Free PMC article. Review.
Upcoming immunotherapeutic combinations for B-cell lymphoma.
Greve P, Meyer-Wentrup FAG, Peperzak V, Boes M. Greve P, et al. Immunother Adv. 2021 Feb 9;1(1):ltab001. doi: 10.1093/immadv/ltab001. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919738 Free PMC article. Review.
Recent advances in immunotherapies against infectious diseases.
Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K, Barth S. Ramamurthy D, et al. Immunother Adv. 2020 Nov 25;1(1):ltaa007. doi: 10.1093/immadv/ltaa007. eCollection 2021 Jan. Immunother Adv. 2020. PMID: 38626281 Free PMC article. Review.
Special Review: The future of Immunotherapy.
Melief CJM. Melief CJM. Immunother Adv. 2020 Nov 25;1(1):ltaa005. doi: 10.1093/immadv/ltaa005. eCollection 2021 Jan. Immunother Adv. 2020. PMID: 36756002 Free PMC article. Review.
Vitamin D3 replacement enhances antigen-specific immunity in older adults.
Chambers ES, Vukmanovic-Stejic M, Turner CT, Shih BB, Trahair H, Pollara G, Tsaliki E, Rustin M, Freeman TC, Mabbott NA, Noursadeghi M, Martineau AR, Akbar AN. Chambers ES, et al. Immunother Adv. 2020 Nov 25;1(1):ltaa008. doi: 10.1093/immadv/ltaa008. eCollection 2021 Jan. Immunother Adv. 2020. PMID: 36284901 Free PMC article.
Introducing Immunotherapy Advances.
Elliott T. Elliott T. Immunother Adv. 2020 Nov 25;1(1):ltaa009. doi: 10.1093/immadv/ltaa009. eCollection 2021 Jan. Immunother Adv. 2020. PMID: 36284897 Free PMC article. No abstract available.